Share Print Save
Myriad Genetics has done a good job identifying the key genes involved in breast cancer and ovarian cancer, and the medical establishment to advocate with the convenience of doing these tests to their patients at risk. But charging $ 3,340 (2,500 euros) for a genetic test costs 20 times less is a bad idea of ??your financial department, by itself, justifies the judgment of the U.S. Supreme Court. The company would do well now to preserve the excellent scientists who have to fire your staff and finance department in full, or at least lowering their salary 20 times. This is the key event versus Molecular Pathology Association Myriad Genetics (12-398) . The rest is a debate tremebundo of essences over the forces of nature and its relation to human invention, not really going to get us nowhere.
One of the more bombastic arguments that have been advanced in this debate is that genes are a product of nature-a piece of body, that is, or even a “force of nature” as has sought a judge in previous cases, and not an invention of the human mind, and therefore can not be patented commercial. An extended position among judges is that a gene could be patented if synthetic, but not if it merely has been isolated from the body of someone. It’s a pointless argument, because in our genomic times the difference between the two is merely rhetorical.
BRCA1, BRCA2, and all others are in the public domain for many years: the reader can access your sequence (atggacctt …) from your mobile phone when he wants and zero cost. That, indeed, has been the main contribution of public human genome project on which the newspapers have spilled ink Iguazu for 15 years. These and the other 20,000 genes that make up our hereditary endowment and operate our cells every second of our lives are a world heritage site, and thanks especially to the U.S. public science and its National Institutes of Health, with important contributions to British and Spanish very few indeed.
is true that in the nineties there were several attempts to patent pharmaceutical sharks genes, ie their mere sequence (atggacctt …), but for the rest were inactivated at the same microsecond that the public project made accessible these 3,000 million letters to everyone, including researchers from private companies, of course. Today no one can patent a gene for the simple reason that any gene is on Google up for grabs want to read it. But genes can do many things, some very clever and important, and companies have to continue to play a big role in that investigation, and therefore patenting their original procedures.
to put a price on things are another story.
No comments:
Post a Comment